ArticleCancer2020

Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.

Valentina Vysotskaia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.